Snyder, J. T., Shen, J., Azmi, H., Hou, J., Fowler, D. H., & Ragheb, J. A. (2007). Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine production. American Society of Hematology.

Snyder, James T., Jijia Shen, Hooman Azmi, Jeannie Hou, Daniel H. Fowler, και Jack A. Ragheb. Direct Inhibition of CD40L Expression Can Contribute to the Clinical Efficacy of Daclizumab Independently of Its Effects On Cell Division and Th1/Th2 Cytokine Production. American Society of Hematology, 2007.

Snyder, James T., et al. Direct Inhibition of CD40L Expression Can Contribute to the Clinical Efficacy of Daclizumab Independently of Its Effects On Cell Division and Th1/Th2 Cytokine Production. American Society of Hematology, 2007.